Inhibrx (INBX) Revenue & Revenue Breakdown
Inhibrx Revenue Highlights
Latest Revenue (Y)
$1.80M
Main Segment (Y)
License, Non-Affiliate
Inhibrx Revenue by Period
Inhibrx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.80M | -17.36% |
| 2022-12-31 | $2.18M | -69.43% |
| 2021-12-31 | $7.13M | -44.37% |
| 2020-12-31 | $12.81M | 40.86% |
| 2019-12-31 | $9.09M | 21.24% |
| 2018-12-31 | $7.50M | -5.66% |
| 2017-12-31 | $7.95M | - |
Inhibrx generated $1.80M in revenue during NA 2023, up -17.36% compared to the previous quarter, and up 24.00% compared to the same period a year ago.
Inhibrx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.63M | 1273.11% |
| 2023-09-30 | $119.00K | 296.67% |
| 2023-06-30 | $30.00K | 76.47% |
| 2023-03-31 | $17.00K | -93.80% |
| 2022-12-31 | $274.00K | -1.44% |
| 2022-09-30 | $278.00K | -60.90% |
| 2022-06-30 | $711.00K | -22.30% |
| 2022-03-31 | $915.00K | -67.74% |
| 2021-12-31 | $2.84M | 13.08% |
| 2021-09-30 | $2.51M | 173.20% |
| 2021-06-30 | $918.00K | 6.37% |
| 2021-03-31 | $863.00K | -68.91% |
| 2020-12-31 | $2.78M | -52.35% |
| 2020-09-30 | $5.83M | 74.75% |
| 2020-06-30 | $3.33M | 282.34% |
| 2020-03-31 | $872.00K | 226.59% |
| 2019-12-31 | $267.00K | -66.37% |
| 2019-09-30 | $794.00K | -20.60% |
| 2019-06-30 | $1.00M | -85.78% |
| 2019-03-31 | $7.03M | 181.28% |
| 2018-06-30 | $2.50M | - |
| 2018-03-31 | $2.50M | - |
Inhibrx generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Inhibrx Revenue Breakdown
Inhibrx Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| License, Non-Affiliate | $1.80M | $2.18M | $10.81M | - |
| License | - | $2.18M | - | - |
| Grant | - | $14.00K | $86.00K | - |
| License, Affiliate - PD-L1 And 4-1BB License Agreement | - | - | - | - |
| License, Affiliate - OX40 License Agreement | - | - | - | $2.00M |
| License, Affiliate | - | - | - | $2.00M |
Inhibrx's latest annual revenue breakdown by segment (product or service), as of Dec 23: License, Non-Affiliate (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License, Non-Affiliate | $100.00K | $1.75M | $30.00K | $17.00K | $278.00K | $711.00K | $915.00K | $2.51M | $918.00K | $863.00K | $3.83M | - | - | - |
| Grant | - | - | - | - | - | - | - | $14.00K | $20.00K | $24.00K | $36.00K | $26.00K | $300.00K | - |
| License | - | - | - | - | $274.00K | $2.84M | - | - | - | - | - | - | - | - |
| License, Affiliate - OX40 License Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00M |
| License, Affiliate | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00M |
| License, Affiliate - PD-L1 And 4-1BB License Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Inhibrx's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License, Non-Affiliate (100.00%).
Inhibrx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MRUS | Merus | $43.95M | $7.33M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| INBX | Inhibrx | $1.80M | - |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| OPT | Opthea | $108.41K | $61.27K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DSGN | Design Therapeutics | - | - |
| DICE | DICE Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CELC | Celcuity | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| MACK | Merrimack Pharmaceuticals | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| ELVN | Enliven Therapeutics | - | - |
INBX Revenue FAQ
What is Inhibrx’s yearly revenue?
Inhibrx's yearly revenue for 2023 was $1.8M, representing a decrease of -17.36% compared to 2022. The company's yearly revenue for 2022 was $2.18M, representing a decrease of -69.43% compared to 2021. INBX's yearly revenue for 2021 was $7.12M, representing a decrease of -44.37% compared to 2020.
What is Inhibrx’s quarterly revenue?
Inhibrx's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.63M, a 1273.11% increase from the previous quarter (Q3 2023), and a 496.35% increase year-over-year (Q4 2022). INBX's quarterly revenue for Q3 2023 was $119K, a 296.67% increase from the previous quarter (Q2 2023), and a -57.19% decrease year-over-year (Q3 2022).
What is Inhibrx’s revenue growth rate?
Inhibrx's revenue growth rate for the last 3 years (2021-2023) was -74.74%, and for the last 5 years (2019-2023) was -80.20%.
What are Inhibrx’s revenue streams?
Inhibrx's revenue streams in c 23 are License, Non-Affiliate
What is Inhibrx’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Inhibrx was License, Non-Affiliate. This segment made a revenue of $1.8M, representing 100.00% of the company's total revenue.